| 0.194 0.014 (7.78%) | 12-29 15:39 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Vyant Bio, Inc. is a biotechnology company focused on identifying treatments for intricate neurological conditions, including both neurodevelopmental and neurodegenerative disorders. The firm leverages a sophisticated central nervous system (CNS) drug discovery platform that integrates human-derived brain organoid models, high-throughput biological screening, and machine learning. Their primary goal is to pinpoint novel or existing small molecule drug candidates for rare genetic CNS diseases like Rett Syndrome, CDKL5 deficiency disorders, and hereditary forms of Parkinson's disease. Additionally, Vyant Bio, Inc. maintains a collaborative agreement specifically for the discovery of Parkinson's Disease therapies. The company's headquarters are located in Cherry Hill, New Jersey.
Fri, 04 Sep 2026
Vyant Bio Inc. (VYNT) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Tue, 26 Dec 2023
Vyant Bio Provides Update on Winddown Activities - Yahoo Finance
Tue, 25 Apr 2023
Why Is TRACON Pharma (TCON) Stock Down 51% Today? - InvestorPlace
Mon, 06 Feb 2023
Two top executives step down as Vyant Bio continues to explore strategic alternatives - The Business Journals
Thu, 03 Nov 2022
Reaction Biology to Acquire U.S. Operations of Vyant Bio - citybiz
Wed, 12 Oct 2022
Michael Brian Mccartney Net Worth (2026) - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|